{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:06:43Z","timestamp":1773022003114,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114372","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:56:51Z","timestamp":1741118211000},"page":"114372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study"],"prefix":"10.1016","volume":"152","author":[{"given":"Fen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114372_bb0005","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung Cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0010","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.21037\/tlcr.2019.05.01","article-title":"What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?","volume":"8","author":"Nesbit","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.intimp.2025.114372_bb0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with Atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.intimp.2025.114372_bb0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0030","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung Cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.114372_bb0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung Cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.intimp.2025.114372_bb0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2217\/imt-2023-0073","article-title":"Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings","volume":"15","author":"Zu","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2025.114372_bb0045","article-title":"Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114372_bb0050","first-page":"11","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy","author":"Rizvi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0055","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1158\/1078-0432.CCR-22-0657","article-title":"Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung Cancer","volume":"28","author":"Schoenfeld","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.114372_bb0060","first-page":"8","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0065","first-page":"11","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","author":"Kluger","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","article-title":"Immunotherapy for small cell lung cancer: mechanisms of resistance","volume":"19","author":"Hamilton","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.114372_bb0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.114372_bb0080","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0085","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.7150\/ijbs.82776","article-title":"Current status in Rechallenge of immunotherapy","volume":"19","author":"Hu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2025.114372_bb0090","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor Rechallenge and resumption: a systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.intimp.2025.114372_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","article-title":"Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis","volume":"140","author":"Giaj Levra","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0100","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","article-title":"Immune checkpoint inhibitors Rechallenge efficacy in non-small-cell lung Cancer patients","volume":"21","author":"Gobbini","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3449660","article-title":"REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in metastatic renal cell carcinoma: An Ambispective multicenter study","volume":"2022","author":"Vauchier","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0110","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2025.114372_bb0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1759-7714.15209","article-title":"Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0120","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review","volume":"11","author":"Kitagawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.intimp.2025.114372_bb0125","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/s41598-024-52034-2","article-title":"Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: A retrospective study","volume":"14","author":"Feng","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.114372_bb0130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2025.114372_bb0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus Apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2025.114372_bb0140","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1002\/cam4.5360","article-title":"Efficacy and safety of anlotinib combined with PD-1\/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2025.114372_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: A phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925003625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:04:46Z","timestamp":1757912686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925003625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"alternative-id":["S1567576925003625"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114372","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114372"}}